Literature DB >> 11167748

Are aberrant BCR--ABL transcripts more common than previously thought?

G A Wilson1, E A Vandenberghe, R C Pollitt, D C Rees, A C Goodeve, I R Peake, J T Reilly.   

Abstract

We report the use of multiplex polymerase chain reaction (PCR), using 4% polyacrylamide gel electrophoresis (PAGE) for the detection of BCR-ABL transcripts in Philadelphia-positive disease. Three out of 50 cases [two out of 37 chronic myeloid leukaemia (CML), one out of 13 acute lymphoblastic leukaemia (ALL)] possessed rare breakpoints; an e19a2 and e13a3 in CML and an e1a3 in the ALL. We suggest that multiplex PCR using 4% PAGE and optimized for smaller transcript detection may lead to a higher detection rate of rare BCR-ABL breakpoints. Multiplex PCR, however, failed to distinguish e13a2 from e1a3 transcripts. Finally, the presence of e13a3 in CML supports the view that abl exon 2 sequences are unnecessary for the pathogenesis of 'classic' CML.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11167748     DOI: 10.1046/j.1365-2141.2000.02471.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  9 in total

1.  Two cases of acute lymphoblastic leukemia with an e1a3 BCR-ABL1 fusion transcript.

Authors:  Sang-Yong Shin; Jin-Hee Cho; Hee-Jin Kim; Jun-Ho Jang; Seung-Tae Lee; Sun-Hee Kim
Journal:  Ann Lab Med       Date:  2014-12-08       Impact factor: 3.464

Review 2.  Ancillary techniques in bone marrow pathology: molecular diagnostics on bone marrow trephine biopsies.

Authors:  Falko Fend; Oliver Bock; Markus Kremer; Katja Specht; Leticia Quintanilla-Martinez
Journal:  Virchows Arch       Date:  2005-10-18       Impact factor: 4.064

3.  Aleukemic Extramedullary Blast Crisis as an Initial Presentation of Chronic Myeloid Leukemia with E1A3 BCR-ABL1 Fusion Transcript.

Authors:  Naoki Miyashita; Masahiro Onozawa; Keito Suto; Shinichi Fujisawa; Nanase Okazaki; Daisuke Hidaka; Hiroyuki Ohigashi; Atsushi Yasumoto; Junichi Sugita; Daigo Hashimoto; Yoshihiro Matsuno; Takanori Teshima
Journal:  Intern Med       Date:  2021-09-11       Impact factor: 1.282

4.  A rare e14a3 (b3a3) BCR-ABL fusion transcript in chronic myeloid leukemia: diagnostic challenges in clinical laboratory practice.

Authors:  Natini Jinawath; Alexis Norris-Kirby; B Douglas Smith; Christopher D Gocke; Denise A Batista; Constance A Griffin; Kathleen M Murphy
Journal:  J Mol Diagn       Date:  2009-06-04       Impact factor: 5.568

Review 5.  A variant transcript, e1a3, of the minor BCR-ABL fusion gene in acute lymphoblastic leukemia: case report and review of the literature.

Authors:  Shinya Fujisawa; Satoki Nakamura; Kensuke Naito; Masahide Kobayashi; Kazunori Ohnishi
Journal:  Int J Hematol       Date:  2008-02-06       Impact factor: 2.490

6.  Optimal Molecular Methods in Detecting p190 (BCR-ABL) Fusion Variants in Hematologic Malignancies: A Case Report and Review of the Literature.

Authors:  Rebecca J Sonu; Brian A Jonas; Denis M Dwyre; Jeffrey P Gregg; Hooman H Rashidi
Journal:  Case Rep Hematol       Date:  2015-04-08

7.  Acute lymphoblastic leukemia with e1a3 BCR/ABL fusion protein. A report of two cases.

Authors:  Bernardo López-Andrade; Francesca Sartori; Antonio Gutiérrez; Lucia García; Vanesa Cunill; María Antonia Durán; Antonia Sampol; Marta Bernués; Julio Iglesias; Rafael Ramos; Josep Lladó; María Sánchez; Juan Carlos Amat; Jordi Martínez-Serra
Journal:  Exp Hematol Oncol       Date:  2016-07-29

8.  Variant BCR-ABL1 fusion genes in adult Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia.

Authors:  Stephen E Langabeer
Journal:  EXCLI J       Date:  2017-10-18       Impact factor: 4.068

9.  Ponatinib induces a sustained deep molecular response in a chronic myeloid leukaemia patient with an early relapse with a T315I mutation following allogeneic hematopoietic stem cell transplantation: a case report.

Authors:  Nuno Cerveira; Rosa Branca Ferreira; Susana Bizarro; Cecília Correia; Lurdes Torres; Susana Lisboa; Joana Vieira; Rui Santos; Fernando Campilho; Carlos Pinho Vaz; Luís Leite; Manuel R Teixeira; António Campos
Journal:  BMC Cancer       Date:  2018-12-07       Impact factor: 4.430

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.